"Purchase Solventum for $70 and Achieve 6.6% Annualized Returns Through Options"
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 21 2025
0mins
Should l Buy SOLV?
Source: NASDAQ.COM
Put Selling and Upside Potential: Selling a put option does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, which depends on the stock price falling significantly.
Risk and Reward Analysis: The potential reward for the put seller is limited to the premium collected, which offers a 6.6% annualized return unless the stock price drops below the strike price of $70.
Market Activity: Recent trading data shows a put:call ratio of 0.72 among S&P 500 components, indicating higher than expected put buying activity compared to historical norms.
Volatility Considerations: The historical volatility of Solventum Corp is calculated at 31%, which, along with fundamental analysis, can help assess the risk-reward balance of selling the April 2026 put option.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SOLV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SOLV
Wall Street analysts forecast SOLV stock price to rise
8 Analyst Rating
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 68.600
Low
79.00
Averages
93.71
High
105.00
Current: 68.600
Low
79.00
Averages
93.71
High
105.00
About SOLV
Solventum Corporation is a global healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer needs. The Company’s segments include MedSurg, Dental Solutions, and Health Information System. MedSurg is a provider of solutions including negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies Original Equipment Manufacturer (OEM). Dental Solutions is a provider of a comprehensive suite of dental and orthodontic products including brackets, aligners, and restorative cement. Health Information Systems provides healthcare systems with software solutions, including computer-assisted physician documentation, and direct-to-bill and coding automation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Middleby Appoints Glenn Eisenberg to Board of Directors
- Board Expansion: The Middleby Corporation announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1, increasing the board to twelve members, which underscores the company's commitment to strategic transformation.
- Extensive Financial Experience: Eisenberg brings a 20-year track record as a public company CFO and senior operating executive, having previously served as CFO at Labcorp, overseeing financial operations in over 100 countries, which is expected to significantly support Middleby's operational initiatives.
- Strategic Focus: Middleby CEO Tim FitzGerald noted that Eisenberg's expertise in financial discipline and capital allocation will be crucial for driving sustainable organic growth, reflecting the company's emphasis on enhancing board capabilities.
- Diverse Leadership Background: Eisenberg currently serves on the boards of two other public companies and has extensive public company governance experience, which will provide valuable oversight for Middleby as it aims to achieve long-term value creation and operational excellence.
See More
SOLVENTUM CORP: UBS Increases Target Price from $79 to $82
- Company Update: UBS has raised the target price for Solventum Corp.
- New Target Price: The new target price is set at $82, up from the previous $79.
See More
Solventum Shares Decline Despite Surpassing Wall Street Earnings Expectations
- Stock Performance: Shares of healthcare supplier Solventum experienced a decline early Friday.
- Earnings Report: The company reported strong fourth-quarter earnings and provided guidance for 2026.
See More
Solventum Corporation Q4 2025 Earnings Call Highlights
- Significant Sales Growth: Solventum reported $2 billion in sales for Q4 2025, reflecting a 3.5% increase year-over-year, despite a 3.7% decline on a reported basis due to the impact of the P&F divestiture and Acera acquisition, demonstrating the company's resilience and growth potential in the market.
- Strategic Acquisition Progress: The acquisition of Acera Surgical positions Solventum in the fast-growing synthetic tissue market, expected to contribute meaningfully to future sales growth while optimizing the existing technology portfolio and enhancing competitive positioning.
- Share Repurchase Program: Solventum announced a $1 billion share repurchase program set to begin in January 2026, aimed at achieving a more balanced capital structure, reflecting management's confidence in the company's future value.
- Optimistic Future Outlook: The company guided for organic sales growth of 2% to 3% in 2026, with operating margins projected to rise to 21% to 21.5%, indicating ongoing improvements in sales leverage and supply chain efficiencies.
See More
Solventum Corporation Q4 Earnings Beat Expectations
- Earnings Beat: Solventum Corporation reported a Q4 non-GAAP EPS of $1.57, exceeding expectations by $0.07, which reflects the company's robust profitability and may enhance investor confidence.
- Revenue Decline: The company generated $2 billion in revenue for Q4, a 3.4% year-over-year decline, yet it surpassed expectations by $40 million, indicating a relatively stable market performance amidst challenges.
- Self-Help Program Progress: Solventum's self-help initiatives are ahead of schedule, and despite negative market sentiment, the company's commitment to achieving long-term growth targets could lay a solid foundation for future performance.
- Analyst Upgrade: KeyBanc has upgraded Solventum's rating, reflecting growing recognition of the company's long-term growth potential, which may attract increased investor interest.
See More
Solventum Corporation Reports Increased Q4 Profit
- Profit Growth: Solventum Corporation reported a fourth-quarter net profit of $63 million, translating to $0.36 per share, which is a significant increase from last year's $30 million and $0.17, indicating improved profitability.
- Adjusted Earnings: Excluding items, the company reported adjusted earnings of $277 million or $1.57 per share, showcasing strong performance in core operations despite a decline in overall revenue.
- Revenue Decline: The company's revenue for the fourth quarter fell to $1.99 billion, a 3.9% decrease from $2.07 billion last year, reflecting challenges in the market environment and competitive pressures.
- Market Reaction: Despite the revenue decline, the profit growth may boost investor confidence, likely leading to a positive impact on the company's future stock performance.
See More
Middleby Appoints Glenn Eisenberg to Board of Directors
- Board Expansion: The Middleby Corporation announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1, increasing the board to twelve members, which underscores the company's commitment to strategic transformation.
- Extensive Financial Experience: Eisenberg brings a 20-year track record as a public company CFO and senior operating executive, having previously served as CFO at Labcorp, overseeing financial operations in over 100 countries, which is expected to significantly support Middleby's operational initiatives.
- Strategic Focus: Middleby CEO Tim FitzGerald noted that Eisenberg's expertise in financial discipline and capital allocation will be crucial for driving sustainable organic growth, reflecting the company's emphasis on enhancing board capabilities.
- Diverse Leadership Background: Eisenberg currently serves on the boards of two other public companies and has extensive public company governance experience, which will provide valuable oversight for Middleby as it aims to achieve long-term value creation and operational excellence.
See More
SOLVENTUM CORP: UBS Increases Target Price from $79 to $82
- Company Update: UBS has raised the target price for Solventum Corp.
- New Target Price: The new target price is set at $82, up from the previous $79.
See More
Solventum Shares Decline Despite Surpassing Wall Street Earnings Expectations
- Stock Performance: Shares of healthcare supplier Solventum experienced a decline early Friday.
- Earnings Report: The company reported strong fourth-quarter earnings and provided guidance for 2026.
See More
Solventum Corporation Q4 2025 Earnings Call Highlights
- Significant Sales Growth: Solventum reported $2 billion in sales for Q4 2025, reflecting a 3.5% increase year-over-year, despite a 3.7% decline on a reported basis due to the impact of the P&F divestiture and Acera acquisition, demonstrating the company's resilience and growth potential in the market.
- Strategic Acquisition Progress: The acquisition of Acera Surgical positions Solventum in the fast-growing synthetic tissue market, expected to contribute meaningfully to future sales growth while optimizing the existing technology portfolio and enhancing competitive positioning.
- Share Repurchase Program: Solventum announced a $1 billion share repurchase program set to begin in January 2026, aimed at achieving a more balanced capital structure, reflecting management's confidence in the company's future value.
- Optimistic Future Outlook: The company guided for organic sales growth of 2% to 3% in 2026, with operating margins projected to rise to 21% to 21.5%, indicating ongoing improvements in sales leverage and supply chain efficiencies.
See More
Solventum Corporation Q4 Earnings Beat Expectations
- Earnings Beat: Solventum Corporation reported a Q4 non-GAAP EPS of $1.57, exceeding expectations by $0.07, which reflects the company's robust profitability and may enhance investor confidence.
- Revenue Decline: The company generated $2 billion in revenue for Q4, a 3.4% year-over-year decline, yet it surpassed expectations by $40 million, indicating a relatively stable market performance amidst challenges.
- Self-Help Program Progress: Solventum's self-help initiatives are ahead of schedule, and despite negative market sentiment, the company's commitment to achieving long-term growth targets could lay a solid foundation for future performance.
- Analyst Upgrade: KeyBanc has upgraded Solventum's rating, reflecting growing recognition of the company's long-term growth potential, which may attract increased investor interest.
See More
Solventum Corporation Reports Increased Q4 Profit
- Profit Growth: Solventum Corporation reported a fourth-quarter net profit of $63 million, translating to $0.36 per share, which is a significant increase from last year's $30 million and $0.17, indicating improved profitability.
- Adjusted Earnings: Excluding items, the company reported adjusted earnings of $277 million or $1.57 per share, showcasing strong performance in core operations despite a decline in overall revenue.
- Revenue Decline: The company's revenue for the fourth quarter fell to $1.99 billion, a 3.9% decrease from $2.07 billion last year, reflecting challenges in the market environment and competitive pressures.
- Market Reaction: Despite the revenue decline, the profit growth may boost investor confidence, likely leading to a positive impact on the company's future stock performance.
See More
